Genmab A/S (NASDAQ:GMAB) Hits New 1-Year Low – Should You Sell?

Genmab A/S (NASDAQ:GMAB)’s stock price reached a new 52-week low on Friday . The stock traded as low as $20.32 and last traded at $20.34, with a volume of 53103 shares. The stock had previously closed at $20.65.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GMAB. BMO Capital Markets reaffirmed an “outperform” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Wednesday, October 16th. Truist Financial lowered their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research report on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Stock Down 2.3 %

The stock’s 50-day simple moving average is $22.15 and its 200 day simple moving average is $25.07. The firm has a market cap of $13.35 billion, a P/E ratio of 19.58, a PEG ratio of 0.67 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same quarter in the previous year, the company earned $0.47 EPS. On average, research analysts forecast that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Several large investors have recently modified their holdings of GMAB. SG Americas Securities LLC grew its holdings in Genmab A/S by 22.8% in the second quarter. SG Americas Securities LLC now owns 36,234 shares of the company’s stock worth $911,000 after purchasing an additional 6,734 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Genmab A/S by 4.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 70,171 shares of the company’s stock worth $1,763,000 after purchasing an additional 3,283 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Genmab A/S by 123.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock valued at $81,000 after buying an additional 1,787 shares during the period. Crossmark Global Holdings Inc. increased its position in Genmab A/S by 11.4% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 70,632 shares of the company’s stock valued at $1,775,000 after buying an additional 7,242 shares in the last quarter. Finally, Ingalls & Snyder LLC raised its stake in Genmab A/S by 29.3% during the 2nd quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock worth $5,772,000 after buying an additional 52,117 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.